[HTML][HTML] Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

…, T Barnetche, ME Truchetet, T Schaeverbeke - BMC medicine, 2015 - Springer
Background Targeting CTLA-4 is a recent strategic approach in cancer control: blocking
CTLA-4 enhances an antitumor immunity by promoting T-cell activation and cytotoxic T …

Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis

B Bannwarth, F Péhourcq, T Schaeverbeke… - Clinical …, 1996 - Springer
Low-dose pulse methotrexate has emerged as one of the most frequently used slow-acting,
symptom-modifying antirheumatic drugs in patients with rheumatoid arthritis (RA) because of …

Incidence and risk of fatal myocardial infarction and stroke events in rheumatoid arthritis patients. A systematic review of the literature.

…, B Fautrel, T Barnetche, T Schaeverbeke - Clinical and …, 2008 - europepmc.org
Background There is substantial evidence of excess cardiovascular morbidity and mortality
in rheumatoid arthritis (RA) patients, but the related studies showed important variations in …

[HTML][HTML] MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease

…, C Dromer, C Richez, T Schaeverbeke… - … England Journal of …, 2018 - Mass Medical Soc
Background Given the phenotypic similarities between rheumatoid arthritis (RA)–associated
interstitial lung disease (ILD)(hereafter, RA-ILD) and idiopathic pulmonary fibrosis, we …

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

…, XL Loët, E Hachulla, T Schaeverbeke… - Arthritis & …, 2010 - Wiley Online Library
Objective The risk of severe infection is a crucial factor in the assessment of the short‐term
risk: benefit ratio of biologic drugs in rheumatoid arthritis (RA). There is no increase in …

Influence of porosity on the mechanical resistance of hydroxyapatite ceramics under compressive stress

JC Le Huec, T Schaeverbeke, D Clement, J Faber… - Biomaterials, 1995 - Elsevier
Calcium phosphate ceramics are biocompatible and may develop interactions with human
living bone tissues. They are used clinically on the surface of orthopaedic implants to …

Th1 (IL-2, interferon-gamma (IFN-γ)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus …

…, V Ranchin, T Schaeverbeke… - Clinical & …, 1999 - academic.oup.com
We investigated the production of IL-2, IFN-γ, IL-10 and IL-4 by PBMC from 24 patients with
SLE and 10 healthy individuals. Basal and mitogen-stimulated (lipopolysaccharide and …

Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre …

…, C Richez, N Mehsen, T Schaeverbeke - Annals of the …, 2018 - ard.bmj.com
Objectives To evaluate the prevalence and type of rheumatic immune-related adverse
events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs), as well as the …

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

…, LH Calabrese, X Mariette, T Schaeverbeke - Annals of the …, 2021 - ard.bmj.com
Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given …

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease

…, E Hachulla, J Morel, T Schaeverbeke… - Annals of the …, 2018 - ard.bmj.com
Objectives Adult-onset Still's disease (AOSD) is a rare systemic autoinflammatory disease;
its management is largely empirical. This is the first clinical study to determine if interleukin …